|
A Phase 1 trial of HF50 to evaluate the safety, tolerability,
pharmacokinetic characteristics, immunogenicity, and preliminary efficacy
in... Bi-specific T-cell engager, Business Wire, Clinical trial, Immuno-Oncology, Investigational New Drug, Neoplasm, T cell |
|
| More about this | ||
|
|
||
| ||